Pay in 4 interest-free payments of $5.35 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
Common side effects include mild pain, redness, or swelling at the injection site
Who Benefits Most from Each Approach B12 Injections Prove Ideal For: Individuals with documented B12 deficiency requiring rapid correction achieve fastest results through injection therapy
PMID 25327251
Any use within that window requires explicit clearance and ongoing supervision from the clinician managing the cancer history
Ready to take the next step toward better health and vitality
